Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Pharma Industry News Why Innovent Biologics and SanegeneBio believe IBI3016 could change hypertension treatment Innovent Biologics and SanegeneBio reveal strong Phase 1 data for IBI3016 at AHA 2025. Discover how this RNAi therapy could redefine hypertension treatment. bySrinathNovember 10, 2025